Chemistry:Ivarmacitinib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Other names | SHR0302 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C18H22N8O2S |
| Molar mass | 414.49 g·mol−1 |
Ivarmacitinib (SHR0302) is a small molecule drug and selective janus kinase 1 (JAK1) inhibitor. It is being developed for ulcerative colitis,[1] eczema, alopecia areata, and graft-versus-host disease.[2][3][4][5][6]
References
- ↑ Chen, Baili; Zhong, Jie; Li, Xiuling; Pan, Feng; Ding, Yijuan; Zhang, Yan; Chen, Hong; Liu, Fei et al. (December 2022). "Efficacy and Safety of Ivarmacitinib in Patients With Moderate-to-Severe, Active, Ulcerative Colitis: A Phase II Study". Gastroenterology 163 (6): 1555–1568. doi:10.1053/j.gastro.2022.08.007. ISSN 1528-0012. https://pubmed.ncbi.nlm.nih.gov/35963369/.
- ↑ Qiu, Huiying; Niu, Jiahua; Sun, Xi; Li, Huajun; Yang, Juan; Huang, Chongmei; Cai, Yu; Zhou, Kun et al. (15 November 2022). "Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT". Blood 140 (Supplement 1): 7624–7624. doi:10.1182/blood-2022-162148.
- ↑ Li, Baoping; Li, Nanyang; Goh, Aik Han; Cao, Haifeng; Irwin, Min Wang; Tong, Xunian; Wang, Jingjing; Wu, Xiaojie et al. (9 May 2023). "A Phase I Study to Evaluate the Safety and Pharmacokinetics of SHR0302 Base Ointment in Healthy Adult Volunteers". Skin Pharmacology and Physiology 36 (2): 76–86. doi:10.1159/000528739. ISSN 1660-5527. https://karger.com/spp/article-abstract/36/2/76/843537/A-Phase-I-Study-to-Evaluate-the-Safety-and?redirectedFrom=fulltext.
- ↑ Zhao, Yan; Zhang, Litao; Ding, Yangfeng; Tao, Xiaohua; Ji, Chao; Dong, Xiuqin; Lu, Jianyun; Wu, Liming et al. (November 2021). "Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical Trial". American Journal of Clinical Dermatology 22 (6): 877–889. doi:10.1007/s40257-021-00627-2.
- ↑ Zhou, Cheng; Yang, Xiumin; Yang, Bin; Yan, Guofu; Dong, Xiuqin; Ding, Yangfeng; Fan, Weixin; Li, Linfeng et al. (November 2023). "A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology 89 (5): 911–919. doi:10.1016/j.jaad.2023.02.063.
- ↑ Ge, Xinyu; Ma, Sheng; Yan, Shu; Wu, Yali; Chen, Chong; Tang, Chongzhuang; Zhan, Yan; Bian, Yi-cong et al. (1 February 2023). "Mass balance study of [ 14 C]SHR0302, a selective and potent JAK1 inhibitor in humans". Xenobiotica 53 (2): 69–83. doi:10.1080/00498254.2023.2176267.
 |  |
